Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults – Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO,...

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency – Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient...